Robert J. DeVita

This study shows that harmine plus exendin-4, when combined with anti-CD3 therapy, promotes beta-cell recovery and reduces immunogenicity, leading to remission of recent-onset type 1 diabetes.

This paper shows harmine, a DYRK1A inhibitor, selectively promotes human beta cell differentiation and function via PKA activation, distinct from other DYRK1A inhibitors.

The paper identifies dopaminylated proteins in the brain, including γCaMKII, and shows its role in synaptic-to-nuclear signaling and memory formation.

The paper characterizes the human SUGCT enzyme, determines its structure, and identifies inhibitors that may lead to new treatments for glutaric aciduria type 1.

This study identifies harmine, 2-2c, and 5-IT as DYRK1A inhibitors that enhance both beta cell proliferation and differentiation, while others fail to induce differentiation.